Taico Oliva Carolina, Musa Ibrahim, Ardalani Fariba, Breslin Joseph, Yang Nan, Moscatello Augustine, Rotsides Janine, Tiwari Raj, Geliebter Jan, Li Xiu-Min
New York Medical College, Valhalla, USA.
Breslin Research Foundation, Taos, NM, USA.
Integr Cancer Ther. 2025 Jan-Dec;24:15347354251332966. doi: 10.1177/15347354251332966. Epub 2025 Jul 24.
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer that typically affects women ages 20 to 50, presenting as an asymptomatic neck mass. Treatment with total or partial thyroidectomy shows an excellent prognosis. However, investigation of non-invasive therapeutic options with minimal adverse effects is ongoing. This study seeks to investigate the K1 cell line, which consists of PTC cells obtained from metastatic tumors of well-differentiated PTC.
Our investigation focuses on a cannabinoid-based product (named BRF1-A) and its potential anti-cancer effects through modulation of gene expression. We investigated its effects on gene expression of p53, c-Myc, and BCL-2 in K1 papillary thyroid cancer cells.
BRF1A was co-cultured with K1 cell line (1 × 10 cells/ml) and incubated at 37°C under 5% CO for 24 and 48 hours. After the culture time points, the cells were harvested, and cell viability was determined via trypan blue exclusion assay. Using qRT-PCR, we determined the effect on the gene expression of TP53, c-Myc, and BCL-2.
Results show that the BRF1A decreased the viability of K1 PTC cells in a dose and time-dependent manner. Within 24 hours, the cannabinoid- containing product increased the gene expression of TP53 and decreased the gene expression of BCL-2 and c-Myc in K1 PTC cells.
The results suggest that the cannabinoid-containing product BRF1A interacts as a potential regulator in well-differentiated thyroid cancer with the upregulation of p53 and downregulation of BLC-2 and c-Myc. Further in vitro and in vivo studies are needed to understand the exact mechanism and therapeutic potential of the cannabinoid-containing products in papillary thyroid cancer.
乳头状甲状腺癌（PTC）是最常见的甲状腺癌，通常影响20至50岁的女性，表现为无症状的颈部肿块。全甲状腺切除或部分甲状腺切除治疗显示出极佳的预后。然而，对具有最小副作用的非侵入性治疗选择的研究仍在进行中。本研究旨在调查K1细胞系，该细胞系由从高分化PTC转移瘤中获得的PTC细胞组成。
我们的研究集中在一种基于大麻素的产品（名为BRF1-A）及其通过调节基因表达产生的潜在抗癌作用。我们研究了其对K1乳头状甲状腺癌细胞中p53、c-Myc和BCL-2基因表达的影响。
将BRF1A与K1细胞系（1×10细胞/ml）共培养，并在37°C、5% CO₂条件下孵育24和48小时。在培养时间点过后，收获细胞，并通过台盼蓝排斥试验测定细胞活力。使用qRT-PCR，我们确定了对TP53、c-Myc和BCL-2基因表达的影响。
结果表明，BRF1A以剂量和时间依赖性方式降低了K1 PTC细胞的活力。在24小时内，含大麻素的产品增加了K1 PTC细胞中TP53的基因表达，并降低了BCL-2和c-Myc的基因表达。
结果表明，含大麻素的产品BRF1A作为一种潜在的调节剂，在高分化甲状腺癌中与p53的上调以及BLC-2和c-Myc的下调相互作用。需要进一步的体外和体内研究来了解含大麻素产品在乳头状甲状腺癌中的确切机制和治疗潜力。
